<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04075032</url>
  </required_header>
  <id_info>
    <org_study_id>AGL2015-64124-R(2)</org_study_id>
    <nct_id>NCT04075032</nct_id>
  </id_info>
  <brief_title>Pomegranate Consumption by Poly-medicated Metabolic Syndrome Patients</brief_title>
  <official_title>Effect of a Pomegranate Extract on Metabolic and Inflammatory Markers, and the Gut Microbiota of Poly-medicated Metabolic Syndrome Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Research Council, Spain</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hospital General Universitario Reina Sofía de Murcia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>National Research Council, Spain</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective is to evaluate whether the medication in polymedicated metabolic syndrome
      patients could determine the effects of a pomegranate extract on i) metabolic markers, ii)
      inflammatory markers, and iii) the modulation of the gut microbiota.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 10, 2018</start_date>
  <completion_date type="Actual">December 31, 2019</completion_date>
  <primary_completion_date type="Actual">July 21, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>Randomized, double-blind, placebo-controlled and crossover trial.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change (1 log units) of Bacteroidetes per gram of feces</measure>
    <time_frame>Change from baseline at 30 days vs placebo</time_frame>
    <description>Modulation of gut microbiota (decrease Firmicutes to Bacteroidetes ratio)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change (10%) of circulating levels of lipopolysaccharide binding protein (LBP)</measure>
    <time_frame>Changes from baseline at 30 days vs placebo</time_frame>
    <description>Evaluation of metabolic endotoxemia</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change (10%) of ghrelin, TNF-α, GLP-1, IL-6, PYY, resistin, HGF, MCP-1, C-Peptide, and BDNF (pg/mL).</measure>
    <time_frame>Changes from baseline at 30 days vs placebo</time_frame>
    <description>Determination of metabolic and inflammatory markers in serum samples.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change (10%) of PAI-1, adiponectin, RBP4, and leptin (ug/mL).</measure>
    <time_frame>Changes from baseline at 30 days vs placebo</time_frame>
    <description>Determination of fibrinolytic, inflammatory and metabolic markers in serum samples</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change (10%) of ICAM-1, VCAM-1, and P-selectin (ng/mL)</measure>
    <time_frame>Changes from baseline at 30 days vs placebo</time_frame>
    <description>Measurement of cell adhesion molecules in serum samples</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change (10%) of blood glucose, total cholesterol, LDLc and HDLc concentrations (mg/dL)</measure>
    <time_frame>Changes from baseline at 30 days vs placebo</time_frame>
    <description>Measurement of serobiochemical variables (blood glucose and lipids levels) in serum samples</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of genotype frequencies for 60 single nucleotide polymorphisms (SNPs) related to the incidence of obesity, metabolism, diabetes and cardiovascular diseases</measure>
    <time_frame>Baseline values at inclusion</time_frame>
    <description>SNP genotyping of patients (DNA extracted from whole blood)</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Metabolic Syndrome</condition>
  <arm_group>
    <arm_group_label>Pomegranate extract-1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Consumption of 2 daily capsules (900 mg pomegranate extract, PE) for 4 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo-1</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Consumption of 2 daily capsules (900 mg microcrystalline cellulose, PLA) for 4 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo-2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Consumption of 2 daily capsules (900 mg microcrystalline cellulose, PLA) for 4 weeks. This arm is the previous PE-1 after crossover and one month of wash-out</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pomegranate extract-2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Consumption of 2 daily capsules (900 mg pomegranate extract, PE) for 4 weeks. This arm is the previous PLA-1 after crossover and one month of wash-out.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Pomegranate extract</intervention_name>
    <description>Pomegranate extract consumption (900 mg/day) for 4 weeks</description>
    <arm_group_label>Pomegranate extract-1</arm_group_label>
    <arm_group_label>Pomegranate extract-2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo (microcrystalline cellulose) consumption (900 mg/day) for 4 weeks</description>
    <arm_group_label>Placebo-1</arm_group_label>
    <arm_group_label>Placebo-2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Body mass index &gt;30 kg/m2 or waist circumference &gt;94/80 cm (males/females) in
             European-Caucasians subjects, plus two of the following:

          -  Triglycerides &gt;150 mg/dL or under treatment against hypertrigliceridemia.

          -  Fasting glucose ≥100 mg/dL

          -  Diagnosed type 2 diabetes mellitus

          -  HDL-cholesterol (mg/dl) &lt;40/50 (males/females) or under treatment against low HDLc
             values.

          -  Systolic blood pressure &gt;130 mmHg o diastolic blood pressure &gt;85 mmHg, or under
             anti-hypertensive drug treatment.

        Exclusion Criteria:

          -  Age under 18 years

          -  Pregnancy or breastfeeding

          -  Antibiotic treatment within one month before inclusion in the trial

          -  Pomegranate allergy or intolerance (known or suspected)

          -  Chronic intestinal inflammatory diseases (ulcerative colitis, Crohn's disease, etc.)

          -  Malignancies

          -  Consumption of botanicals or dietary supplements within one month before the inclusion
             and during the trial.

          -  Consumption of ellagitannin-rich sources within one week before the inclusion and
             during the trial (pomegranate, walnuts, strawberries, raspberries, tea, blackberries
             and oak-aged wine).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Juan C Espín, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Spanish National Research Council (CSIC)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Spanish National Research Council (CSIC)</name>
      <address>
        <city>Murcia</city>
        <zip>30100</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>June 2019</verification_date>
  <study_first_submitted>August 22, 2019</study_first_submitted>
  <study_first_submitted_qc>August 28, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 30, 2019</study_first_posted>
  <last_update_submitted>March 12, 2020</last_update_submitted>
  <last_update_submitted_qc>March 12, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 13, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>metabolic syndrome</keyword>
  <keyword>pomegranate</keyword>
  <keyword>gut microbiota</keyword>
  <keyword>polyphenol</keyword>
  <keyword>polymedication</keyword>
  <keyword>inflammation</keyword>
  <keyword>obesity</keyword>
  <keyword>diabetes</keyword>
  <keyword>hypertension</keyword>
  <keyword>hyperlipidemia</keyword>
  <keyword>urolithins</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metabolic Syndrome</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

